Skip to main content
. Author manuscript; available in PMC: 2012 Jan 3.
Published in final edited form as: Clin Pharmacol Ther. 2011 Aug 31;90(4):568–574. doi: 10.1038/clpt.2011.194

Figure 2.

Figure 2

Event-free survival over 1 year of follow-up in Sinai Hospital of Baltimore (a) caucasian and (b) African-American patients treated with clopidogrel and aspirin following percutaneous coronary intervention, stratified by PON1 Q192R genotype. Post-discharge ischemic events were defined as myocardial infarction (the occurrence of ischemic symptoms and troponin I value greater than the upper limit of normal), ischemic stroke, stent thrombosis (definite stent thrombosis according to the Academic Research consortium criteria), unplanned target-vessel revascularization (revascularization of vessel treated at the time of study enrollment), hospitalization for coronary ischemia without revascularization (hospitalization for chest pain with evidence of ischemia on electrocardiogram and no evidence of myocardial infarction as assessed by troponin I levels), and death secondary to any cardiovascular cause. Blue and red lines represent rs662 Q/Q and R/– genotypes, respectively. All analyses were adjusted for age and sex.